Jiangsu Chia Tai-Tianqing Pharmaceutical Co. Ltd., commonly referred to as Chia Tai-Tianqing, is a prominent player in the pharmaceutical industry, headquartered in Jiangsu, China. Established in 1994, the company has made significant strides in the development and production of innovative medicines, particularly in the fields of oncology, cardiovascular health, and infectious diseases. With a strong operational presence across various regions in China and a growing international footprint, Chia Tai-Tianqing is recognised for its commitment to quality and research-driven solutions. The company’s core offerings include a diverse range of pharmaceuticals and biopharmaceuticals, distinguished by their efficacy and safety profiles. Notably, Chia Tai-Tianqing has achieved a leading market position, underscored by its robust pipeline of products and strategic partnerships, which enhance its competitive edge in the global pharmaceutical landscape.
How does Jiangsu Chia Tai-Tianqing Pharmaceutical Co. Ltd's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Jiangsu Chia Tai-Tianqing Pharmaceutical Co. Ltd's score of 32 is higher than 57% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Jiangsu Chia Tai-Tianqing Pharmaceutical Co. Ltd, headquartered in China, currently does not report specific carbon emissions data for the most recent year. The company is a current subsidiary of Sino Biopharmaceutical Limited, which may influence its climate commitments and emissions reporting. As of now, Jiangsu Chia Tai-Tianqing Pharmaceutical has not established any documented reduction targets or climate pledges. The absence of specific emissions data and reduction initiatives suggests that the company may still be in the early stages of developing a comprehensive climate strategy. Given its affiliation with Sino Biopharmaceutical Limited, any potential emissions data or climate commitments may be inherited from this parent company. However, no specific figures or targets have been provided in the available information. In summary, Jiangsu Chia Tai-Tianqing Pharmaceutical Co. Ltd is currently lacking in detailed emissions reporting and climate commitments, reflecting a broader context within the pharmaceutical industry where many companies are still working towards establishing robust sustainability frameworks.
Access structured emissions data, company-specific emission factors, and source documents
2021 | 2022 | 2023 | |
---|---|---|---|
Scope 1 | 21,711,730 | 00,000,000 | 00,000,000 |
Scope 2 | 253,214,050 | 000,000,000 | 000,000,000 |
Scope 3 | - | - | - |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Jiangsu Chia Tai-Tianqing Pharmaceutical Co. Ltd is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.